China Regenerative Medicine International Limited reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was HKD 231.61 million compared to HKD 282.9 million a year ago. Net income was HKD 4.56 million compared to HKD 51.83 million a year ago.

Basic earnings per share from continuing operations was HKD 0.02 compared to HKD 0.2 a year ago. Diluted earnings per share from continuing operations was HKD 0.02 compared to HKD 0.2 a year ago. Basic earnings per share was HKD 0.02 compared to HKD 0.1 a year ago.